论文部分内容阅读
Objective :To investigate the antitumor effect of dendritic cell (DC) modified by gp96-peptide complexes both in vitro and in vivo. Methods :Gp96-peptide complexes were acquired from H22 liver cancer cells in mice. DC were cultured from bone marrow cells and modified by gp96-peptide complexes. Spleen lymphocytes of mice were activated by modified DC and the cytotoxicity were detected by 51Cr release method. Modified DC, gp96-peptide complexes and inactivated H22 cells were injected into mice bearing H22 liver cancer cells to observe the levels of IL-10, IFN-γ in serum and the alteration of proportions of CD8+-IFN γ+ and CD8+- IL-10+ cells, CD4+-IFNγ+ and CD4+- IL-10+ cells. Results :DC modified by gp96-peptide complexes can activate spleen lymphocyte and the latter can specifically kill H22 cells but not Ehrilich ascites carcinoma cells. Modified DC can improve the hosts antitumor immune response and the proportions of Th1 cells, inhibiting tumor growth. Conclusion: Gp96-peptide complexes can activate DC effectively, making DC a good vaccine.